Dr.Ankita aishwarya

Dr. SANTOSH G. HONAVAR, Dr.HARIKA REGANI

Abstract

To assess the outcomes in retinoblastoma (RB) treated with triple-drug intraarterial chemotherapy (IAC). It was retrospective interventional study of 145 eyes of 112 RB patients from 2013 to 2019 treated with super-selective triple-drug (topotecan, carboplatin and melphalan) IAC. The mean age at IAC was 22.8m with mean follow up of 42.1m. Of 126 treatment-naïve eyes, ICRB Groups were A (n=0), B (n= 10), C (n=16), D (n=59), and E (n=41). Primary IAC was provided in 92 eyes and secondary IAC in 53 eyes, local consolidation in 128 (88%) and a median of 6 cycles of intravenous chemotherapy (IVC) in 81(56%). Group B and C showed 100% regression. Complications included vitritis in 4 (2.7%), sterile inflammation in 2 (1.4%) and ptosis in 1 (0.7%). Eye salvage was achieved in all in Group B and C, 54 (92%) in Group D and 22 (54%) in Group E. None developed systemic metastasis. Triple drug superselective IAC is remarkably effective in Group B-D RB, while modest success is possible in Group E.

Full Text